AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule.
Selumetinib 10 mg & 25 mg capsule is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).
The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses.
Shares of AstraZeneca Pharma India Ltd. was last trading in BSE at Rs. 3084 as compared to the previous close of Rs. 3099.15. The total number of shares traded during the day was 1799 in over 553 trades.
The stock hit an intraday high of Rs. 3119.95 and intraday low of 3079.7. The net turnover during the day was Rs. 5564736.